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Abstract
The efficacy of a drug depends on its binding affinity to the therapeutic target
and pharmacokinetics. Deep learning (DL) has demonstrated remarkable progress
in predicting drug efficacy. We develop MolDesigner, a human-in-the-loop web
user-interface (UI), to assist drug developers leverage DL predictions to design
more effective drugs. A developer can draw a drug molecule in the interface. In the
backend, more than 17 state-of-the-art DL models generate predictions on important
indices that are crucial for a drug’s efficacy. Based on these predictions, drug
developers can edit the drug molecule and reiterate until satisfaction. MolDesigner
can make predictions in real-time with a latency of less than a second.
A drug’s efficacy depends on various factors. Among others, two crucial factors are binding affinity
that measures the strength of drug-protein target interactions and pharmacokinetics (PK) indices that
measure how the body reacts to the drug [13]. PK indices include absorption, distribution, metabolism,
excretion, and toxicity (ADMET). However, to obtain these values in a traditional wet lab setting
is notoriously expensive and time-consuming [4]. Deep learning (DL) models have recently shown
high accuracy in predicting the binding affinity and various ADMET indices [9, 11, 8].
Demonstrated Technology. Here, we propose a humans-in-the-loop web user interface (UI) called
MolDesigner to help drug developers leverage DL to improve drug designs. Given a drug molecule,
MolDesigner predicts various important indices from state-of-the-art DL models, powered by our
DeepPurpose library [8]. They provide real-time feedback to help drug developers modify the
molecular structure and iterate on this process until the models start to show the drug candidate
has reasonable measures and properties. This way, drug developers can leverage DL models to
rapidly design a drug that has not only high efficacy to the target protein but also has ideal ADMET
properties. MolDesigner is especially useful for lead optimization where drug developer makes
chemical modification on the molecular structure to improve the drug’s quality.
In MolDesigner, the user (drug designer) first specifies the target protein (e.g., amino acid sequence) of
interest. The user can then begin drawing the initial drug candidate or reading the molecular structure
from a file using any popular chemical data format. In less than one second latency, MolDesigner
returns predictions, representing binding affinity to the target protein along with predictions for 16
crucial PK indices. The user can then review predictions and make further chemical modifications
based on the expert knowledge, thus iteratively refining the drug candidate’s structure until the
candidate molecule is predicted to have the desired properties. This draw-predict cycle can be
repeated as needed until the user is satisfied. The user can also specify the DL model to make
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Figure 1: The web user-interface of MolDesigner.
predictions. We provide five DL models for binding affinity prediction and three models for each of
the PK properties. In total, more than 50 DL models power the backend of MolDesigner.
Implementation. We use DeepPurpose [8] to rapidly generate DL models for drug-target interaction
(DTI) and drug property predictions. We then use Gradio [1] to set up the web UI. We use the
BindingDB dataset for DTI prediction and collect 16 datasets from various sources for the PK
indices. The PK indices include solubility, lipophilicity, Caco-2, human-intestinal-absorption (HIA),
P-gp inhibition, bioavailability, blood-brain-barrier (BBB), plasma-protein-binding rate (PPBR),
various CYP inhibitors, half-life, clearance, and clinical toxicity. We provide the following DL
models for drug-protein binding affinity prediction. For modeling drugs, we use Message Passing
Neural Network (MPNN) [6], Convolutional Neural Network (CNN) [10], Deep Neural Network
(DNN) on Morgan fingerprints [12]. For modeling proteins, we have CNN and DNN, which are
trained on proteins’ amino acid composition fingerprints. For drug property prediction, MolDesigner
supports MPNN, CNN, and DNN on Morgan fingerprints. The Gradio interface also supports taking
screenshots and flagging outputs for easy tracking and future reference.
Novelty. MolDesigner makes the following contributions. 1) Existing drug discovery interfaces focus
on one task [5, 2, 3], such as DTI or one of ADMET prediction tasks. In contrast, MolDesigner is the
first to integrate 16 ADMET predictions and binding affinity in a single click. 2) Earlier work focuses
on a demo of prediction model where a separate output page is generated after user input [5, 2, 3]. In
contrast, MolDesigner is designed to keep humans in the loop. MolDesigner focuses on molecular
design, enabling rapid predictions, exploration, and interactive adjustments as the user modifies
chemical reactions. It provides a unified interface where the user can see both drug molecules and
predicted values on the same page. 3) MolDesigner is powered by over 50 state-of-the-art DL models,
whereas prevailing tools are only designed to use one model. For ADMET prediction, the current
web UI mainly uses classic machine learning methods. 4) MolDesigner is fast. The overall prediction
latency is less than one second, allowing rapid molecular design.
Interaction with Virtual Audience. We will start with a demo showcasing how our framework aids
drug design. Then, depending on the audience’s background, we will design two interactive activities.
For a computational audience with no knowledge of drug development, we will have a game where
users will play the role of chemists developing drugs for one of the COVID-19 targets [7]. We
will start from the drug that already has a high affinity to the target and let the user make chemical
modifications. As the user draws drugs, we will demonstrate how predicted drug properties vary
with molecular structure. To engage with drug discovery experts in the audience, we will ask them
to propose a target of interest and a potential drug molecule. We will ask them what changes to the
molecular structure would they introduce to improve predicted properties, and see if our model can
corroborate their hypothesis, followed by discussion. For the audience to engage with the UI, we will
use remote control features to draw on the screen.
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